IMV Inc
TSX:IMV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
IMV Inc
TSX:IMV
|
9.2m CAD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
46.8B USD |
Loading...
|
Market Distribution
| Min | -9 940 586.9% |
| 30th Percentile | -85.9% |
| Median | -7.8% |
| 70th Percentile | 5.5% |
| Max | 60 777.6% |
Other Profitability Ratios
IMV Inc
Glance View
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for IMV Inc is -9 937.8%, which is above its 3-year median of -10 111.7%.
Over the last 3 years, IMV Inc’s Net Margin has decreased from -3 786.1% to -9 937.8%. During this period, it reached a low of -25 951.2% on Jun 30, 2022 and a high of -3 786.1% on Dec 31, 2019.